
VectorY Therapeutics Doses First Participant in Phase 1/2 PIONEER-ALS Trial of VTx-002 for ALS
VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with Amyotrophic Lateral Sclerosis (ALS) VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the first participant has been…











